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Abstract 
 
Objective/setting: This study assessed the effectiveness of milled and whole chia seed in altering disease risk 
factors in overweight, postmenopausal women using a metabolomics approach. 
Design/intervention: Subjects were randomized to chia seed (whole or milled) and placebo (poppy seed) groups, 
and under double-blinded procedures ingested 25 g chia seed or placebo supplements each day for 10 weeks. 
Subjects: Subjects included 62 overweight (body–mass index 25 kg/m2 and higher), non-diseased, 
nonsmoking, postmenopausal women, ages 49–75 years, with analysis based on the 56 subjects who 
completed all phases of the study. 
Outcome measures: Pre- and post-study measures included body mass and composition, blood pressure 
and augmentation index, serum lipid profile, inflammation markers from fasting blood samples, plasma fatty 
acids, and metabolic profiling using gas chromatography–mass spectrometry with multivariate statistical 
methods including principal component analysis and partial least-square discriminant analysis (PLS-DA). 
Results: Plasma a-linolenic acid (N = ALA) increased 58% (interaction effect, p = 0.002) and eicosapentaenoic acid 
(EPA) 39% ( p = 0.016) in the milled chia seed group (N = 14) compared to nonsignificant changes in the whole 
chia seed (N = 16) and placebo (N = 26) groups. Pre-to-post measures of body composition, inflammation, blood 
pressure, augmentation index, and lipoproteins did not differ between chia seed (whole or milled) and placebo 
groups (all interaction effects, p > 0.05). Global metabolic difference scores for each group calculated through 
PLS-DA models were nonsignificant (Q2Y < 0.40), and fold-changes for 28 targeted metabolites associated with 
inflammation and disease risk factors did not differ between groups. 
Conclusions: Ingestion of 25 g/day milled chia seed compared to whole chia seed or placebo for 10 weeks by 
overweight women increased plasma ALA and EPA, but had no influence on inflammation or disease risk 
factors using both traditional and metabolomics-based measures. 
 
 
Introduction 
 
he essential fatty acid, a-linolenic acid (ALA; 18:3n-3), 
is present in various seeds, nuts, and vegetable oils and 
can be metabolically converted to long-chain n-3 
polyunsaturated fatty acids (n-3 PUFAs), including 
eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic 
acid (DPA; 22:5n-3, and docosahexaenoic acid (DHA; 
22:6n-3).1,2 U.S. male and female adults consume about 1.7 
and 1.3 g ALA, respectively, slightly above the Adequate 
Intake recommendations of 1.6 and 1.1 g/day.3,4 
Consumption of long-chain n-3 PUFAs EPA and DHA 
from fish and fish-oil supplements reduces disease risk fac- 
tors, counters the metabolic syndrome, and decreases all- 
cause mortality, cardiac and sudden death, and possibly 
stroke.5–8 These health benefits have prompted the U.S. Food 
and Drug Administration to support a qualified health claim 
status for EPA and DHA. 
The reluctance of U.S. adults to increase fish intake, and 
concerns over fish farming and accumulation of pollutants in 
fish have accelerated interest in  botanical sources  of n-3 
PUFAs such as flaxseed, chia seed, walnuts, and algae.9–11 
 
 
 
Additionally, estimates are that the ratio of omega-6 (n-6) 
linoleic acid (LA) to omega-3 (n-3) ALA increased from 6.4 to 
10.0 during the 20th century, resulting in decreased tissue 
concentrations of EPA and DHA.12 Plant n-3 PUFAs are 
abundant and readily available, and are often contained in 
foods that are high in dietary fiber, minerals, polyphenols, 
and other components with potential health value. A 
growing number of epidemiologic studies support a 
variety of potential health benefits from a higher than 
normal chronic ALA intake including decreased incidence 
of diabetes, bone fracture, and depression.13–15 The cardio-
protective effect of ALA in humans, however, is unclear, and 
studies differ widely regarding influences on disease risk 
factors such as blood lipid profiles, blood pressure, insulin 
resistance, fibrinogen, endothelial function, and systemic 
inflammation.7–9,16–18 About one third of ingested ALA is 
oxidized, and enzymatic conversion to EPA and DHA is 
relatively inefficient in humans.1,2 
Chia seed (Salvia hispanica L.) is an oilseed native to southern 
Mexico and northern Guatemala, and contains 4.4 g ALA (57% 
of total fat) per 25 g serving.19–24 In rats, consumption of chia 
seeds and chia seed oil counters dyslipidemia and visceral 
adiposity, improves insulin sensitivity and glucose tolerance, 
and induces tissue lipid redistribution associated with cardio- 
protection.19,25,26 These animal studies support the strategy of 
using n-3 PUFAs supplements to help control chronic 
inflammation and disease risk factors in overweight/obese 
individuals, but human data are limited and conflicting. In a 
previous study with 76 overweight men and women, it was 
shown that daily ingestion of 50 g whole chia seed (soaked in 
water for 10 minutes) over a 12-week period increased 
plasma ALA (24%) but not EPA, with no change in body 
mass, inflammation, or disease risk factors.20 Research  with 
fleed  suggests that ingestion of milled flaxseed or flaxseed 
oil results in higher plasma ALA levels than whole flaxseed, 
and beneficial changes in risk factors.9,21–23 Thus, one purpose 
of this second randomized community  trial was  to 
compare  ingestion of milled and whole chia seed on the 
plasma ALA and EPA response, and potential effects on 
traditional biomarkers of cardiovascular disease. 
Additionally, ALA ingestion may be associated with subtle 
changes in inflammation and disease risk factors that are 
best captured through global and targeted metabolomics 
profiling, the primary outcome for this study.24 
Correspondingly, it was hypothesized that ingestion of milled 
chia seed would increase plasma ALA and EPA, resulting in a 
significant change in metabolites related to influence on and 
disease risk factors. 
 
Methods 
Subjects 
Subjects included 24 overweight (body–mass index [BMI] 
25–29.9 kg/m2) and 38 obese (BMI 30 kg/m2 and higher), 
non-diseased, nonsmoking, postmenopausal women, ages 
49–75 years, who were recruited through local advertising. 
Postmenopausal women were selected as subjects to remove 
the potential confounding effect of the menstrual cycle on the 
outcome measures in this study. Subjects were apparently 
healthy with no overt chronic disease (specifically, coronary 
heart disease, stroke, cancer [other than skin], diabetes 
mellitus, rheumatoid arthritis), and not taking dietary 
supplements or medications known to influence 
inflammation (in 
particular, nonsteroidal anti-inflammatory drugs). Subjects 
agreed to maintain normal dietary and physical activity 
patterns during the 10-week study, make no formal attempts 
to lose body weight, and avoid flaxseed, flaxseed oil, and fish 
oil. Fish and seafood were limited to no more than one 
serving per week, and subjects were instructed to limit intake 
of omega-6 fatty acids by lowering use of corn, soybean, 
safflower, sunflower, and similar oils, and substituting 
moderate amounts of olive and canola oil. Subjects also 
agreed to be randomized to chia seed or placebo groups. 
Written informed consent was obtained from each subject, 
and the experimental procedures were approved by the 
institutional review board of Appalachian State University. 
 
Research design 
Subjects were randomized to chia seed (whole or milled) 
and placebo groups, and under double-blinded procedures 
ingested chia seed or placebo supplements daily for 10 weeks. 
Body composition, blood pressure, augmentation index, and 
blood samples were taken from all subjects pre- and post- 
study after an overnight fast. Diet records and questionnaire 
responses to assess potential adverse effects and adherence to 
the supplementation regimen were administered prestudy, 
and after 5- and 10-week supplementation. The food records 
were analyzed using a computerized dietary assessment 
program (Food Processor, ESHA Research, Salem, OR). The 
symptom logs included questions on digestive health 
(constipation, heartburn, bloating, diarrhea, and nausea), 
hunger levels (morning, afternoon, and evening), energy 
levels (morning, afternoon, and evening), sickness (fever, 
cough, sore throat, stuffy nose, runny nose, and 
headache), pain (joint, muscle, and back), allergies, stress 
level, focus/con- centration, and overall well-being. 
Subjects indicated responses using a 12-point Likert scale, 
with 1 relating to ‘‘none at all,’’ 6 ‘‘moderate,’’ and 12 ‘‘very 
high.’’ Subject compliance was monitored by incorporating 
three laboratory visits during the study and regular e-mail 
correspondence. 
 
Chia seed and placebo supplements 
Chia seed (whole and milled) and placebo supplements 
were prepared by Dole Packaged  Foods, LLC (Westlake 
Village, CA). Whole poppy seed was used as the placebo 
because it is similar to chia seed in appearance, energy, 
dietary fiber, protein, and mineral content, but has no 
ALA. Subjects were told that supplements could be whole 
or mil- led seed, and received chia seed or poppy seed 
supplements in 25-g packets (opaque packaging material). 
Subjects used one 25-g packet each day and ingested the 
chia or poppy seed supplements throughout each day for 
10 weeks within fruit juice and other beverages, yogurt, on 
salads and cooked vegetables, or on breakfast cereal. 
Subjects were instructed to consume the supplement raw 
and not heat it in any way, including cooking, baking, 
boiling, or microwaving. 
 
Body composition 
Height was measured using a stadiometer, while body 
mass and body composition were measured using a Tanita 
bioelectrical impedance scale (Tanita Corporation of Amer- 
ica, Inc., Arlington Heights, IL). Testing took place between 
7:00  am  and  9:30  am  both  prestudy  and  after  10  weeks 
 
 
Table 1. Subject Characteristics (Mean – Standard Error) 
 
 
Variable 
Whole chia seed 
(N = 16) 
Milled chia seed 
(N = 14) 
Placebo (poppy seed) 
(N = 26) 
 
p-Value 
Age (years) 60.4 – 1.6 57.2 – 1.7 58.5 – 1.1 0.363 
Stature (m) 1.65 – 0.01 1.63 – 0.01 1.63 – 0.01 0.355 
Body mass (kg) 90.0 – 4.5 88.8 – 3.3 87.3 – 2.5 0.829 
BMI (kg/m2) 32.9 – 1.3 33.5 – 1.5 33.1 – 0.9 0.940 
BMI, body mass index. 
 
supplementation. Subjects were measured while they were 
standing erect, wearing light clothing, with bare feet on the 
analyzers’ foot pads. 
 
Blood measures, lipoproteins, blood 
pressure, augmentation index 
Blood samples were drawn from an antecubital vein with 
subjects in the seated position for at least 15 minutes. Blood 
samples were drawn at 7:00 am–9:30 am, with all subjects 
having avoided food and beverage intake other than water 
for at least 9 hours. A serum lipid panel and comprehensive 
diagnostic chemistry panel was performed by the authors’ 
clinical hematology laboratory. Blood pressure was 
measured by technicians following a 15-minute seated rest 
after an overnight fast. The SphygmoCor Central Blood 
Pressure System and Pulse Wave Velocity Assessment 
System (AtCor Medical, Atasca, IL) was used to measure 
arterial stiffness and the augmentation index. The 
SphygmoCor system de- rives a calibrated blood pressure 
waveform at the ascending aorta from a peripheral 
pressure waveform, recorded non- invasively at the radial 
artery using a high-fidelity pressure transducer. 
Augmentation index was calculated as the ratio of 
amplitude of the pressure wave above its systolic shoulder to 
the total pulse pressure, and then normalized to a resting 
heart rate of 75 beats per minute. 
 
Plasma ALA, EPA, DPA, and DHA 
Plasma ALA, EPA, DPA, and DHA were analyzed as 
previously described.20 The HP 6890N gas chromatograph 
(Agilent Technologies, Palo Alto, CA) equipped with a 5975B 
Inert XL MSD mass spectrometer detector and a DB-23 GC 
column (60 m · 250 lm · 0.25 lm) from J&W Scientific (Agi- 
lent Technologies) was used to separate the methyl esters of 
the extracted fatty acids. Fatty-acid concentrations were 
calculated in relation to the heptadecanoic acid methyl ester 
internal standard peak. 
 
Plasma Cytokine Measurements 
and C-Reactive Protein 
Total plasma concentrations of nine inflammatory 
cytokines (interleukin-6 [IL-6], tumor necrosis factor a 
[TNFa], granulocyte-macrophage colony-stimulating 
factor [GM- CSF], interferon gamma c (IFNc), IL-1b, IL-2, 
IL-8, IL-10, IL-12p70) were determined using an 
electrochemiluminescence- based solid-phase sandwich 
immunoassay (Meso Scale Discovery, Gaithersburg, MD). 
All samples and provided standards were analyzed in 
duplicate, and the intra-assay coefficient of variation (CV) 
ranged from 1.7% to 7.5%, and the interassay CV ranged 
from 2.4% to 9.6%, for all cytokines 
measured. The minimum detectable concentration of IL-6 was 
0.27 pg.mL - 1, TNFa 0.50 pg.mL - 1, GM-CSF 0.20 pg.mL - 1, 
IFNc 0.53 pg.mL - 1, IL-1b 0.36 pg.mL - 1, IL-2 0.35 pg.mL - 1, IL-8 
0.09 pg.mL- 1, IL-10 0.21 pg.mL- 1, and IL-12p70 1.4 pg.mL - 1. Pre- 
and post-exercise samples for the cytokines were analyzed 
on the same assay plate to decrease interkit assay variability. 
High- sensitivity C-reactive protein (CRP) was measured using 
an LX- 20 clinical analyzer (Beckman Coulter Electronics, Brea, 
CA). 
 
Metabolomics procedures 
All samples (both plasma extracts and standards for the 
internal library) were analyzed on an Agilent 7890A GC 
system coupled to an Agilent 5975C EI/CI Mass Selective 
Detector (Foster City, CA). The raw data files generated by 
gas chromatography-mass spectrometry (GC-MS) were 
converted to NetCDF format. The converted data were 
processed using ChromaTOF software (v4.24, Leco Co., CA) 
including baseline de-nosing, smoothing, peak picking, and 
peak signal alignment (signal-to-noise ‡ 30). Metabolite an- 
notation was performed by comparing unknown signal 
patterns from the study samples to those of reference 
standards from an internal library containing 
approximately 600 human metabolites (Sigma-Aldrich, St. 
Louis, MO) established on the GC-MS system. Commercial 
libraries including the NIST library 2008 and LECO/Fiehn 
Metabolomics Li- brary for GC-MS metabolome data 
(similarity threshold of 70%) were also used for additional 
compound annotation. Heptadecanoic acid was added to 
the study samples as an internal standard to monitor 
analytical variations during the entire sample preparation 
and analysis processes, and precision was calculated by 
injecting six randomly selected samples five times. The 
average CV for heptadecanoic acid was less than 5%. The 
mean CV of the internal standard across the entire sample 
analysis (158 injections) was 15.3%. 
 
Statistical procedures 
Data are reported as mean – standard error. Table 1 data 
were analyzed using one-way analysis of variance (ANO- 
VA). Data in Tables 2 and 3, and Figure 1A,B were analyzed 
using a 3 (group) · 2 (time) repeated-measures ANOVA be- 
tween-subjects model, with pre-to-post-supplementation 
changes calculated and compared using Student’s t-test. Diet 
record and symptom log data were analyzed in a similar 
fashion using a 3 · 3 repeated-measures ANOVA. For the 
metabolomics data (Fig. 2), all initial mathematical 
calculations including peak signal compensations, 
normalization to internal standards, and univariate 
analyses (nonparametric Mann-Whitney-Wilcoxon test) 
were performed using custom scripts in MATLAB R2010a 
(MathWorks, Inc., Natick, MA). The data set was mean-
centered and autoscaled (scaled to 
 
 
Table 2. Pre- and Poststudy Body Mass and Composition, Serum Glucose, Cholesterol, C-Reactive 
Protein, Systolic Blood Pressure, and Vascular Augmentation Indexa in Female Subjects Consuming 
Whole or Milled Chia Seed, or Placebo Supplements for 10 Weeks (Mean – Standard Error) 
Whole chia seed Milled chia seed Placebo (poppy seed) 
Variable (N = 16) (N = 14) (N = 26) 
Interaction 
p-value 
 
 
Body mass (kg) 
Baseline 
 
90.0 – 4.4 
 
88.8 – 3.3 
 
87.3 – 2.5 
 
0.281 
10 weeks 90.8 – 4.4 88.5 – 3.0 87.1 – 2.5  
Body fat (%)     
Baseline 37.1 – 1.8 37.3 – 1.2 37.2 – 0.9 0.668 
10 weeks 38.8 – 1.9 39.0 – 1.2 38.0 – 1.0  
Serum glucose (mmol/L) 
Baseline 5.09 – 0.15 5.32 – 0.22 5.23 – 0.08 0.629 
10 weeks 5.29 – 0.16 5.45 – 0.25 5.31 – 0.10  
Serum cholesterol (mmol/L) 
Baseline 5.46 – 0.26 5.35 – 0.34 5.56 – 0.18 0.805 
10 weeks 5.48 – 0.19 5.25 – 0.29 5.48 – 0.19  
Serum C-reactive protein (mg/L) 
Baseline 4.26 – 0.95 4.04 – 0.88 5.71 – 1.15 0.975 
10 weeks 4.12 – 0.84 3.84 – 0.75 5.66 – 0.90  
Systolic blood pressure (mm Hg) 
Baseline 140 – 3.8 140 – 5.2 140 – 4.9 0.746 
10-weeks 140 – 4.5 136 – 4.7 141 – 4.2  
Augmentation index (mm Hg)a 
Baseline 30.8 – 2.2 31.1 – 2.2 28.6 – 1.8 0.448 
10 weeks 33.4 – 2.1 31.4 – 2.2 33.4 – 1.8  
aAugmentation index normalized to a heart rate of 75 beats/min. 
 
unit variance) prior to statistical analysis. Multivariate 
statistical analyses including principal component analysis 
(PCA) and partial least square–discriminant analysis (PLS- 
DA) were performed using SIMCA-P 12.0.1 + (Umetrics, 
Umeå , Sweden). PCA was initially used to detect data 
outliers, clustering, and classification trends without a 
priori knowledge of the sample set. PLS-DA was used to 
visualize the difference between global metabolic profiles 
for the three groups. In PCA and PLS-DA, each spatial 
dot in the K- dimensional space represents an individual 
observation with color-coded grouping information. R2X 
and R2Y represent the fraction of the variance of X 
matrix and Y matrix, respectively, while Q2Y suggests the 
predictive accuracy of the model. Cumulative values of R2X, 
R2Y, and Q2Y close to 1 indicate an excellent model with a 
reliable predictive ability. In practice, Q2Y values of 0.4 or 
greater indicate a reliable model. To validate the model 
against overfitting, a default seven-round cross-validation in 
SIMCA-P software package was carried out with 1/7th of the 
data being excluded from the modeling in each round. Using 
this method, the Y value for each subject was predicted 
using a model from which that subject was excluded during 
the model building and all the predictions were collated. Fold 
changes on selected metabolites related to inflammation 
and disease risk factors 
 
Table 3. Pre- and Post-study Plasma Cytokine Levels in Female Subjects Consuming 
Whole or Milled Chia Seed, or Placebo Supplements for 10 Weeks (Mean – Standard 
Error) 
 
 
Variable 
Whole chia seed 
(N = 16) 
Milled chia seed 
(N = 14) 
Placebo (poppy seed) 
(N = 26) 
Interaction 
p-Value 
Plasma IL-6 (pg/mL)     
Baseline 2.18 – 0.38 2.31 – 0.53 2.91 – 0.74 0.785 
10 weeks 2.17 – 1.58 2.38 – 0.66 2.47 – 0.44  
Plasma TNF-a (pg/mL) 
Baseline 6.00 – 0.41 7.55 – 0.63 6.92 – 0.45 0.543 
10 weeks 5.82 – 0.38 7.47 – 0.71 7.15 – 0.68  
Plasma IL-8 (pg/mL) 
Baseline 
 
5.55 – 1.24 
 
5.17 – 0.72 
 
4.87 – 0.43 
 
0.871 
10 weeks 4.65 – 0.59 4.77 – 0.41 4.43 – 0.31  
Plasma IL-10 (pg/mL) 
Baseline 
 
2.98 – 0.85 
 
4.75 – 0.98 
 
2.92 – 0.75 
 
0.444 
10 weeks 2.69 – 0.48 4.20 – 0.67 2.90 – 0.52  
IL, interleukin; TNF, tumor necrosis factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 1.   Plasma a-linolenic acid (ALA) 
(A) and eicosapentaenoic acid (EPA) 
(B) pre- and post-10 weeks supple- 
mentation with chia seed (whole or 
milled) or placebo (poppy seed). 
* represents P < 0.025. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Table  4)  were  compared  between  groups  using  Mann- 
Whitney-Wilcoxon. 
 
Results 
 
Subject characteristics for the three study groups are listed 
in Table 1, with no group differences found for age, stature, 
body mass, and BMI. Of the 62 subjects enrolled into the 
study, 6 (all from the placebo group) failed to complete all 
study requirements. Each of the 6 subjects leaving the study 
had difficulty consuming the poppy seeds, and 4 left the 
study within the first week. The primary problem reported 
by subjects in the poppy seed group was mouthfeel and 
seeds lodging between the teeth. Subjects completing the 
study consumed all of the chia seed and placebo supplied to 
them for the study as assessed during laboratory visits at 
weeks 5 and 10. Responses to a post-study questionnaire 
revealed that 35 of 56 subjects did not know what 
supplement they were ingesting (chia seed or poppy seed), 
with 14 subjects guessing correctly and 7 guessing 
incorrectly. 
Macronutrient and micronutrient  intake assessed from 
prestudy and 5- and 10-week 3-day food records did not 
differ between whole chia seed, milled chia seed, and 
placebo groups during the study (data not shown, all 
interaction p-values > 0.05). Symptoms for digestive health, 
hunger, energy level, illness,pain,stress,  
focus/concentration,  and 
 
overall well-being as assessed from pre-study and 5- and 
10- week symptoms logs did not differ significantly 
between chia seed and placebo groups (data not shown). 
Plasma ALA increased 58.4% (interaction effect, p = 0.002), 
and EPA 38.6% ( p = 0.016), in the milled chia seed group 
compared to nonsignificant changes in the whole chia seed 
and placebo groups (Fig. 1A and B). Plasma DPA and DHA 
increased 21.1% and 16.5% in the milled chia seed group, but 
these changes were not significant compared to placebo (data 
not shown). 
Body mass and composition remained stable during the 
10-week study, and pre-to-post-study values did not 
differ between groups (Table 2). The pattern of change 
over time did not differ between groups for serum glucose, 
cholesterol, CRP, systolic blood pressure, and augmentation 
index (Table 2), and for low-density lipoprotein (LDL)-
cholesterol, high- density lipoprotein (HDL)-cholesterol, 
serum triglycerides, diastolic blood pressure, and all 
components in the comprehensive diagnostic chemistry 
panel (data not shown, all interaction p-values > 0.05). 
Data on four of the nine plasma cytokines measured in 
this study are summarized in Table 3. The pattern of change 
over time did not differ between whole chia seed, milled chia 
seed, and placebo groups for each of these variables, or for 
GM-CSF, IFNc, IL-1b, IL-2, or IL-12p70) (data not shown, 
interaction effects, all p > 0.05). 
 
 
 
 
FIG. 2. Score plots from partial least square–discriminant analysis model visualize the global metabolic differences between 
pre-supplementation and post-supplementation in the whole chia seed group (WA, whole chia seed pre-supplementation; 
WB, whole chia seed post-supplementation), and for the milled chia seed group ( MA and MB), and placebo (PA and 
PB). Differences between groups were not significantly different (Q2Y £ 0.40). 
 
 
Score plots from the PLS-DA model visualize the global 
metabolic differences between pre-supplementation and 
post- supplementation in the whole chia seed group 
(WA and WB), the milled chia seed group (MA and MB), 
and placebo (PA and PB) as shown in Figure 2. The Q2Y 
scores of the two PLS-DA models were below 0.4, which 
indicates that the global metabolic profile difference of the 
three groups was non-significant. Fold-change scores for 
28 selected metabolites related to inflammation and disease 
risk factors did not differ between groups (Table 4). 
 
Discussion 
Chia seed supplements are a rich source of ALA, and were 
consumed without adverse digestive or mental symptoms by 
our female, postmenopausal subjects for 10 weeks. Of the 62 
original subjects, 56 complied with all phases of the research 
project, with difficulty in ingesting the poppy seed placebo 
emerging as the primary reason why 6 individuals dropped 
out of the study. Ingestion of 25 g of milled but not whole 
chia seeds per day for 10 weeks resulted in a significant 
increase in plasma ALA and EPA relative to placebo, but no 
group differences were measured for inflammation and 
various measures of disease risk factors as determined by 
both traditional biomarkers and global and targeted 
metabolic profiling. 
Ingestion of 25 g/day chia seed increased dietary ALA 
intake by 4.4 g/day, substantially above the 1.1 g/day U.S. 
adult female average.3 However, plasma ALA and EPA were 
elevated only with milled chia seed intake, with 
nonsignificant changes measured following ingestion of 
whole chia seed. In the previous study, plasma ALA 
increased 24% in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
et al.28  showed no effect of 8-weeks’ supplementation with 
flaxseed oil capsules (increasing ALA to 5% of total energy 
  intake) on serum CRP or plasma IL-6 in obese men and 
 
aMetabolites were verified by internal standard library. Fold 
change was calculated by the ratio of mean rank between two 
groups using the Mann-Whitney-Wilcoxon test; a positive value 
means a higher concentration in poststudy compared to prestudy, 
and vice versa for negative values. 
 
 
 
male and female adults after 12 weeks of ingesting a large 
quantity (50 g/day) of water-soaked whole chia seed,20 
substantially below the 58% increase measured in the current 
study after 10 weeks of ingesting 25 g/day milled (but not 
whole) chia seed. Austria et al.21 also reported significant 
increases in plasma ALA when subjects ingested 30 g/day 
milled but not whole flaxseed over a 3-month period. Thus, 
milled chia seed, consistent with results from studies using 
flaxseed, delivers ALA to the human body better than whole 
chia seed. 
After ingestion, ALA is almost completely absorbed and is 
(1) oxidized to carbon dioxide and water, or (2) incorporated 
into tissue lipids, or (3) utilized in eicosanoid synthesis. Small 
amounts of ALA are lost during sloughing of skin and other 
epithelial cells.1,2 Approximately 15%–35% of ALA is 
catabolized to carbon dioxide for energy, with less than 1% 
converted to DHA.1,2 The fractional conversion of ALA to 
EPA is 0.3% to 8% in men, and up to 21% in women.2 A 58% 
increase in plasma ALA was measured after 
supplementation with 10 weeks milled chia seed, with a 
significant 39% increase in plasma EPA. These results are 
similar to those of others using similar research designs but 
with ground flaxseed.21,23 
women. Reviews also indicate that ALA supplementation has 
inconsistent or null effects on vascular function and blood 
pressure, in concert with the current findings.17,33 
Our data are in partial disagreement with Vuksan et al.34 
This study utilized a single-blind crossover design with 20 
adults with type 2 diabetes who were given 37 g/day chia 
seed or wheat bran for 12 weeks, with a 4–6-week washout 
period. Chia seed supplementation was related to a 6.3 mm 
Hg decrease in systolic blood pressure, a 40% reduction in 
CRP, and a 21% drop in vonWillebrand factor (vWF), with 
no changes in body mass or blood total cholesterol, LDL 
cholesterol, HDL cholesterol, or triglycerides. Much of the 
change in CRP, vWF, and systolic blood pressure in this 
study, however, was due to contrasting increases in these 
measures during the wheat bran supplement period, and are 
inconsistent with most other well-controlled ALA-supple- 
mentation studies. Crossover designs in studies of this type 
pose several challenges, including carryover effects from the 
washout period (which often cannot be specified), and 
compliance issues due to the prolonged total study period. 
 
Conclusions 
Milled compared to whole chia seed supplementation for 
10 weeks resulted in higher plasma ALA and EPA levels. 
Nonetheless, these data combined with those from the 
authors’ previous publication20 do not support the short-
term strategy of having postmenopausal, overweight 
women use whole or milled chia seed supplements (25–50 
g/day) high in 
 
Despite a corresponding increase in plasma ALA, subjects in the 
milled chia seed group experienced nonsignificant changes in a 
variety of risk factor–related outcome measures including lipid 
profiles, blood pressure, augmentation index, and inflammation. 
Metabolomics is the measurement of small molecules or 
metabolites present in biologic samples such as biofluids, tissues, 
and cellular extracts to elucidate the effect of a particular 
stimulus on metabolic pathways. In this study, GC-MS methods 
were utilized to measure metabolic profiles in pre- and post-
supplementation serum samples in combination with 
commercial metabolite libraries and an internal library of 
approximately 600 internal standards for compound 
annotation.24 It was hypothesized that global and targeted 
metabolomics profiling would capture subtle perturbations in 
metabolites associated with inflammation and disease risk factors 
from chia seed ALA intake, but the data were nonsupportive. 
The authors were unable to find any other study using 
metabolomics to investigate ALA supplementation and potential 
influences on human health and disease. The use of 
metabolomics in nutritional sciences is gaining momentum, and 
should improve understanding regarding the health benefits and 
underlying molecular pathways related to dietary 
interventions.24 Most human studies using flaxseed or other 
ALA supplements have failed to show significant or meaningful 
changes in traditional measures of inflammation or the blood 
lipid profile, in concert with the current findings and in contrast 
to results from studies using fish oil supplements.7,9,27–32 A re-
view of five ALA supplementation studies reported an in-
consistent effect of ALA on the blood lipid profile.7 Nelson 
 
 
ALA to help lower chronic inflammation or improve blood 
pressure, vascular function, and blood lipid profiles over a 
10–12-week period. This conclusion is strengthened by the 
lack of group differences over time in both traditional 
disease-related biomarkers and global and targeted 
metabolomics procedures. Whether or not these findings 
can be applied to younger adults remains to be determined 
in subsequent investigations. The typical serving size for 
chia seed is 4–12 g, and we tested intake levels at the upper 
limits of human consumption, but without measurable 
influences on health. Future research is warranted to test 
higher ALA intake levels using chia seed oil. These 
findings, however, should not discourage individuals from 
using chia seed and other ALA-rich foods. These foods are 
nutrient dense, and high, chronic ALA intake has been 
associated in epidemiologic investigations with multiple 
health benefits.8,13–15 
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